Results 61 to 70 of about 5,275 (178)
Food Frontiers, Volume 7, Issue 2, March 2026.Hyperuricaemia is a chronic metabolic disorder arising from impaired purine metabolism, exhibiting marked gender disparities in its prevalence. Daidzein, possessing oestrogen‐like effects, promotes uric acid excretion and improves hepatic and renal function, thereby presenting potential utility as an adjunctive therapeutic agent for hyperuricaemia ...
Zicheng Zhu +9 more
wiley +1 more source
Current issues in the practical use of allopurinol in patients with gout and hyperuricemia
Современная ревматологияThe cornerstone of the treatment of gout and hyperuricemia (HU) is the use of urate-lowering drugs, primarily xanthine oxidase inhibitors. Allopurinol, which has been used to treat gout for six decades, is the first line urate-lowering therapy (ULT ...
M. S. Eliseev
doaj +1 more source
The genetics of gout: towards personalised medicine?
BMC Medicine, 2017 Over the last decade, there have been major advances in the understanding of the genetic basis of hyperuricaemia and gout as well as of the pharmacogenetics of urate-lowering therapy.
Nicola Dalbeth +2 more
doaj +1 more source
Development of a multivariable improvement measure for gout
Arthritis Research & Therapy, 2020 Background Gout is a heterogeneous inflammatory disease with numerous clinical manifestations. A composite means to assess the impact of therapy on numerous aspects of gout could be useful.
Naomi Schlesinger +3 more
doaj +1 more source
Clinical Outcomes and Management in Late Diagnosed Siblings Affected With Attenuated GSD Ib
JIMD Reports, Volume 67, Issue 2, March 2026.ABSTRACT Glycogen storage disease 1b (GSD1b) typically presents in early infancy with poor fasting tolerance, hepatomegaly, and neutropenia. We report two siblings who were diagnosed with GSD1b in adulthood. Both had a normal fasting tolerance throughout childhood and, as adults, were able to fast for at least 16 h without developing hypoglycaemia. The
Gregory Lynch +5 more
wiley +1 more source
Uricases: reflections on recent developments in the management of challenging gout patients [PDF]
Exploration of Musculoskeletal DiseasesOral urate-lowering therapy (ULT) is key to treating gout. However, many patients receiving oral ULT do not achieve the target serum urate (SU) levels, partly because some patients cannot tolerate or have contraindications to their use, mainly due to ...
Naomi Schlesinger, Dan Kaufmann
doaj +1 more source
The NLRP3 Inflammasome: Mechanisms of Activation, Regulation, and Therapeutic Opportunities
MedComm, Volume 7, Issue 3, March 2026.Diverse diseases converge on NLRP3. We depict a discovery‐to‐clinic track: high‐throughput/phenotypic screens, structure‐guided design, and modality innovation (allosteric inhibitors, interface blockers, degraders) deliver third‐generation, disease‐tailored NLRP3 control.
Chan Zou +5 more
wiley +1 more source
Journal of Medical Case ReportsBackground Gout, characterized by monosodium urate crystal deposition, rarely involves the nasal septum, with only a few reported cases. Such unusual presentations can mimic other conditions, necessitating prompt and accurate diagnosis.
Weikun Chen +5 more
doaj +1 more source
Battle of the strategies: diet versus drug therapy for gout
Современная ревматологияThe best results in combating gout are achieved through a combination of diet and drug therapy. Urate-lowering therapy, which includes febuxostat, has been shown to be more effective and convenient than diet when it comes to achieving and maintaining ...
O. V. Zhelyabina +2 more
doaj +1 more source
Practical application of national clinical guidelines for the management of gout (preliminary data)
Современная ревматология, 2020 The 2018 national guidelines for the management of gout provide a consistent scheme for urate-lowering drugs; however, the possibility of achieving uric acid (UA) targets in its use has not been studied.Objective: to evaluate the effectiveness and safety
M. N. Chikina +2 more
doaj +1 more source